(359) Healthcare Resource Utilization in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Study Results

Background: : Immune thrombocytopenia (ITP) is an autoimmune disorder marked by low platelet counts (PCs), which may increase bleeding risk and require ongoing medical care. Avatrombopag (AVA) is an FDA-approved treatment for adults with chronic ITP which aims to increase PCs. Clinical trials and real-world studies have shown AVA’s efficacy in achieving target PC levels, but real-world data on AVA’s impact on healthcare resource utilization (HRU) is limited. The REAL-AVA 2.0 study examined clinical effectiveness and HRU among adult patients (pts) treated with AVA in routine ITP management in the US.

Objective: : To assess ITP-related inpatient (IP), emergency department (ED), and outpatient (OP) visits following AVA treatment among adult pts with primary ITP

Methods: : REAL-AVA 2.0 was a retrospective, multi-site chart review of pts with primary ITP who initiated AVA (index date) from 07/2019 – 12/2024 across 11 U.S. medical centers. Pts were required to have complete medical records for 3 months pre-index (baseline) and ≥6 months post-index unless the patient died. The follow-up (FU) period spanned from index until earliest of death, end of data or study end. ITP-related visits were evaluated during the baseline and FU periods, with FU visits assessed while the pt remained on AVA, for up to 1 year in 3-month intervals (Q1–Q4). A visit was classified as ITP-related if it was associated with ITP, ITP treatment, or related complications. Quarterly FU analyses included only pts with adequate FU through the end of each respective quarter.

Results: : The study included 177 pts; 151 (85%) had sufficient FU for Q1 analysis, 131 (74%) for Q2, 110 (62%) for Q3, and 95 (54%) for Q4. At index, pts had a mean (standard deviation [SD]) age of 56 (19) years and a mean (SD) ITP disease duration of 5.4 (9.0) years. In the 12 months post-AVA initiation, ITP-related HRU declined consistently across all visit types. The proportion of pts with any ITP-related IP admission dropped from 25.4% at baseline to 7.3% in Q1, 4.6% in Q2, 1.8% in Q3, and 1.1% in Q4. ED visits followed a similar trend: 18.6% of pts had ≥1 visit during the baseline vs. 7.3% in Q1, 3.8% in Q2, 3.6% in Q3 and 1.1% by Q4. OP visits also declined from 63.8% of pts at baseline to 56.3% in Q1, 52.7% in Q2, 50.0% in Q3, and 49.5% in Q4. The mean number of ITP-related OP visits declined from 3.1 visits during the baseline to 1.0 visit in Q4.

Conclusions: : Real-world data from the REAL-AVA 2.0 study suggest that treatment with AVA is associated with sustained reductions in ITP-related HRU.

Sponsorship:: Sobi, Inc.